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procedure, physician visits, and contraceptive method failures.
Effectiveness was deﬁned as both control of uterine bleed and
contraception success. We studied three clinical scenarios: sce-
nario 1 compared LNG-IUS with OC in women who responded
to initial trials of OCs; scenario 2 compared surgery with LNG-
IUS among women who did not respond to an initial trial of
OCs; and scenario 3 compared LNG-IUS and OC for women
who are naïve to medical therapy. In all scenarios, surgery fol-
lowed if medical therapy failed. RESULTS: In scenario 1, LNG-
IUS was both more effective (92% vs. 90.4%) and less expensive
($2796 vs. $4711) than OC. In scenario 2, surgical management
was slightly more effective than LNG-IUS (95.5% vs. 92.0%
success rate) but at a much higher cost ($4m853 vs. $2,796 per
woman), and was associated with an additional cost of approx-
imately $60,000 per additional successfully treated woman. In
scenario 3, LNG-IUS achieved similar outcomes compared to
OCs (92% vs. 93.6%) but at a much lower cost ($2796 vs.
$4895). The results of the model were robust over changes of
assumptions and variations of key variables. CONCLUSIONS:
The treatment strategy with LNG-IUS was the most cost-
effective approach to managing AUB, regardless of whether or
not a woman had tried or failed OC therapy.
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OBJECTIVES: Published data on costs associated with treating
privately insured patients with hepatocellular carcinoma (HCC)
or metastatic liver disease (MLD) are limited. This study evalu-
ated health resource use and medical care costs in newly diag-
nosed HCC and MLD patients. METHODS: Patients diagnosed
with HCC or MLD in 2002 were identiﬁed from a nationally
representative private payer claims database by ICD-9 diagnosis
codes, using the date of the ﬁrst diagnosis as the “index date”.
Patients were required to be 18 years of age or older, with no
prior HCC or MLD diagnosis, and continuously enrolled in a
health plan. Health resource use and medical care costs were
tracked over one year. RESULTS: The study included 297 HCC
and 846 MLD patients. The mean age for all patients was 56.8
years and 41% were male. MLD patients had signiﬁcantly higher
inpatient admissions versus HCC patients (2.1 vs. 1.5, p <
0.001), while the mean aggregate hospital days was signiﬁcantly
longer in HCC patients (16.5 vs. 14.2, p < 0.001). MLD patients
also had signiﬁcantly greater emergency room, outpatient hos-
pital, and physician ofﬁce visits (p < 0.05). Total mean medical
costs were signiﬁcantly higher in MLD patients ($93,786) versus
HCC patients ($37,203, p < 0.001). These higher costs were due
primarily to signiﬁcantly greater ancillary costs in MLD patients
($54,671 vs. $5,903, p < 0.001), which include costs associated
with chemotherapy. All differences remained signiﬁcant after
adjusting for differences in age and sex. CONCLUSIONS:
Among managed care patients newly diagnosed with HCC or
MLD, signiﬁcantly higher 1-year health resource use and medical
care costs were found for MLD patients. The difference in overall
costs was due primarily to the higher use of ancillary services
among MLD patients. These ﬁndings provide important new
data for evaluating the economic impact of treating HCC and
MLD patients.
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OBJECTIVES: Estimate national trends in mammography
screening use among elderly Medicare beneﬁciaries for the period
of 1998 to 2001; determine the extent to which socio-
demographic, clinical, and access factors are associated with 
disparities in screening use. METHODS: A secondary data
analysis of the Medicare Current Beneﬁciary Survey (MCBS) was
conducted. Community-dwelling women aged >65 years who
completed the MCBS at least once during the survey years of
1998 to 2001 were included. Having had a mammogram in the
past year was determined by a participant’s response to the ques-
tion “have you had a mammogram or a breast x-ray since a year
ago?”, or by a Medicare claim coded with a mammogram pro-
cedure in the calendar year. Multivariate logistic regression was
used to estimate the association between the likelihood of having
had mammogram in the past year and factors, such as socio-
demographic, biological, and access factors. Sampling weights
were used to reﬂect national estimates of Medicare beneﬁciaries.
Standard errors were adjusted for clustering and stratiﬁcation in
the complex sampling design. RESULTS: A total of 10,757
females 65 years of age or older responded to the MCBS from
1998 to 2001 (weighted N = 34 million). Over half (54%, 95%
CI 53%–55%) of the respondents had mammogram in the past
year. Annual mammography screening rates increased over time,
from 49% in 1998 to 58% in 2001. In adjusted models, there
was no signiﬁcant racial or ethnic disparity in mammography
use, but the other socio-demographic factors remained signiﬁ-
cantly associated with lower odds of mammography use. CON-
CLUSIONS: Mammography screening rates increased notably
between 1998 and 2001 in the Medicare population. While no
racial or ethnic disparities in screening rates were noted in this
study, lower income, less education, no insurance and being
unmarried were identiﬁed as barriers to breast cancer screening
for elderly Medicare beneﬁciaries.
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OBJECTIVE: In the late 1990’s, a U.S. health policy initiative
recommended that colorectal cancer screening begin at age 50
for all adults. Shortly thereafter, Medicare began paying for
screening colonoscopy in average risk persons. In the years that
followed, the mix of procedures performed to evaluate colon
health in Medicare beneﬁciaries changed; colonoscopy proce-
dures increased and other colorectal cancer screening procedures
decreased. We conducted this study to evaluate trends in col-
orectal cancer screening procedure volumes in private-pay
patients between 2000 and 2004. METHODS: A nationally rep-
resentative private payer claims database was used to identify
patient records with claims for colonoscopy, ﬂexible sigmoi-
doscopy, double-contrast barium enema, and fecal occult blood
test (FOBT) during 2000–2004. CPT and HCPCS procedure
codes were used to identify patient records with claims for the
procedures of interest. Only patients aged 18+ were included in
the analysis. RESULTS: Patients in the study sample averaged 53
years of age and were 60% female. From 2000 to 2004 the pro-
portion of screening procedures performed relative to the
number of plan members increased 38% (8% to 11%). Relative
